This study reviewed the Trial to Assess Chelation Therapy (TACT), which examined EDTA (ethylenediamine tetraacetic acid) chelation therapy's effectiveness in reducing cardiovascular events, particularly in patients with diabetes. The study found that EDTA chelation therapy led to a modest reduction in cardiovascular events in diabetic patients (p
